Compare OSUR & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | EARN |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.1M | 200.3M |
| IPO Year | 2000 | 2012 |
| Metric | OSUR | EARN |
|---|---|---|
| Price | $3.01 | $4.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $5.38 |
| AVG Volume (30 Days) | 437.4K | ★ 580.7K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 21.60% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $167,064,000.00 | N/A |
| Revenue This Year | $4.48 | $8.43 |
| Revenue Next Year | $7.76 | $24.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.08 | $4.33 |
| 52 Week High | $4.22 | $6.08 |
| Indicator | OSUR | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 23.56 |
| Support Level | $2.98 | N/A |
| Resistance Level | $3.12 | $5.36 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 52.66 | 1.95 |
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.